8,369 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Bought by CenterBook Partners LP

CenterBook Partners LP bought a new position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 8,369 shares of the company's stock, valued at approximately $522,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in TransMedics Group during the 4th quarter valued at $22,861,000. Emerald Advisers LLC lifted its holdings in TransMedics Group by 146.3% in the fourth quarter. Emerald Advisers LLC now owns 371,711 shares of the company's stock worth $23,176,000 after buying an additional 220,804 shares during the period. FIL Ltd boosted its position in TransMedics Group by 28.0% during the 4th quarter. FIL Ltd now owns 1,000,358 shares of the company's stock valued at $62,372,000 after acquiring an additional 218,961 shares in the last quarter. Principal Financial Group Inc. grew its holdings in shares of TransMedics Group by 260.1% during the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company's stock worth $31,759,000 after acquiring an additional 146,115 shares during the period. Finally, State of Michigan Retirement System purchased a new position in shares of TransMedics Group in the 4th quarter valued at approximately $6,734,000. 99.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a report on Wednesday, March 26th. Canaccord Genuity Group reissued a "buy" rating and set a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Finally, JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $75.00 target price (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $122.70.

Remove Ads

TransMedics Group Stock Performance

Shares of TransMedics Group stock traded up $0.34 during trading on Tuesday, hitting $87.18. 1,255,749 shares of the company's stock traded hands, compared to its average volume of 1,337,395. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $177.37. The business has a 50-day simple moving average of $71.19 and a 200-day simple moving average of $80.67. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The stock has a market capitalization of $2.93 billion, a P/E ratio of 92.75 and a beta of 2.14.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.